In the left ventricles of 19 patients with advanced heart failure, researchers discovered a striking pattern: a protein called PERM1, nearly absent in all their hearts before treatment, returned to near-normal levels only in those whose hearts learned to beat stronger again. This finding, reported in the Journal of the American Heart Association, offers the first molecular fingerprint of recovery in human heart failure—a disease that affects more than 6 million people in the United States.
The study emerged from a collaboration between Junco Warren, a cardiovascular molecular researcher at Virginia Tech's Fralin Biomedical Research Institute, and cardiologist Stavros Drakos at University of Utah Health, who analyzed heart tissue collected from patients treated with left ventricular assist devices, or LVADs. These mechanical pumps shoulder the workload of a failing heart, giving the organ a chance to rest. Yet only some patients experience genuine recovery—until now, the biological reasons remained a mystery.
Researchers collected tissue samples from the left ventricular apex during LVAD implantation and again during device removal or transplantation, comparing hearts that had bounced back from those that had not. The results were unambiguous. Patients whose cardiac function improved showed PERM1levels restored to near-normal after LVAD support. In non-responders, the protein remained suppressed. "This is the first muscle-specific molecular signal linked to recovery in human heart failure," Warren said.
The significance runs deeper than identification alone. PERM1 regulates how heart cells produce and use energy—a fundamental problem in heart failure, where the organ's ability to contract weakens as it struggles to generate enough fuel. Recovery was associated with normalization of stress-related metabolic pathways, suggesting that restoring PERM1 helps the heart escape the vicious cycle where energy loss and reduced contractility reinforce each other. Preclinical work from Warren's lab has already shown that increasing PERM1 improves heart function in experimental models and may prevent heart failure altogether.
The discovery opens two parallel pathways forward. PERM1 now qualifies as a potential biomarker—a measurable sign that could help clinicians predict which patients will recover under LVAD support and which may need different interventions. It also emerges as a target for new therapies. Current medications manage heart failure symptoms but do not repair the underlying muscle damage. A PERM1-focused approach, by contrast, could directly target cardiomyocytes—the heart muscle cells themselves—and restore both energy production and the heart's ability to contract. "Current therapies help manage heart failure, but they do not repair the heart muscle itself," Warren noted. "Our findings point to a pathway that directly targets cardiomyocytes and restores both energy production and contractile function, the two core deficits in heart failure."
The team is already moving toward clinical application. Warren and members of her research group have co-founded a company dedicated to developing PERM1-based gene therapies. While researchers still cannot say whether PERM1 directly drives recovery or simply reflects it, the protein now offers what Warren calls "a clear window into the biology of how recovery happens." For millions living with failing hearts, that window may soon open into a new way forward.